Literature DB >> 11802031

The value of enhanced magnetic resonance imaging in the evaluation of endocochlear disease.

Joseph L Hegarty1, Sandy Patel, Nancy Fischbein, Robert K Jackler, Anil K Lalwani.   

Abstract

BACKGROUND: Gadolinium-enhanced magnetic resonance imaging (GdMRI) is routinely used in the evaluation and management of suspected retrocochlear pathology such as vestibular schwannoma. However, its value in the evaluation and diagnosis of cochlear pathology associated with sensorineural hearing loss (SNHL) has been less clear. STUDY
DESIGN: Retrospective review of case histories and imaging studies of patients with SNHL and cochlear enhancement on GdMRI diagnosed between 1998 and 2000.
RESULTS: Five patients with SNHL who required gadolinium administration to establish the diagnosis of endocochlear disease were identified. Diagnosed lesions included an intralabyrinthine schwannoma, intracochlear hemorrhage, radiation-induced ischemic change, autoimmune labyrinthitis, and meningogenic labyrinthitis. In these illustrative cases, the GdMRI demonstrated intrinsic high signal or contrast enhancement within the cochlea and labyrinth in the absence of a retrocochlear mass. In one patient with meningogenic labyrinthitis, cochlear enhancement on MRI led to prompt cochlear implantation before the potential development of cochlear ossification.
CONCLUSION: Our experience suggests that GdMRI plays a crucial role in the diagnosis of cochlear pathology associated with sensorineural hearing loss and may directly impact patient management.

Entities:  

Mesh:

Year:  2002        PMID: 11802031     DOI: 10.1097/00005537-200201000-00002

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  15 in total

1.  Intralabyrinthine Schwannomas: Disease Presentation, Tumor Management, and Hearing Rehabilitation.

Authors:  Baishakhi Choudhury; Matthew L Carlson; Daniel Jethanamest
Journal:  J Neurol Surg B Skull Base       Date:  2019-03-01

Review 2.  Vertigo and hearing loss.

Authors:  F J Wippold; P A Turski
Journal:  AJNR Am J Neuroradiol       Date:  2009-09       Impact factor: 3.825

3.  Differential diagnosis and prognosis of T1-weighted post-gadolinium intralabyrinthine hyperintensities.

Authors:  F Dubrulle; R Kohler; C Vincent; P Puech; O Ernst
Journal:  Eur Radiol       Date:  2010-06-10       Impact factor: 5.315

4.  Volumetric in vivo imaging of intracochlear microstructures in mice by high-speed spectral domain optical coherence tomography.

Authors:  Hrebesh M Subhash; Viviana Davila; Hai Sun; Anh T Nguyen-Huynh; Alfred L Nuttall; Ruikang K Wang
Journal:  J Biomed Opt       Date:  2010 May-Jun       Impact factor: 3.170

5.  Intralabyrinthine schwannomas: imaging diagnosis and classification.

Authors:  K L Salzman; A M Childs; H C Davidson; R J Kennedy; C Shelton; H R Harnsberger
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-08       Impact factor: 3.825

6.  Bilateral intracochlear schwannomas in a patient with no genetic or clinical features of neurofibromatosis type 2.

Authors:  S Withers; S K Plontke; R Boeddinghaus; J Kuthubutheen; M Atlas
Journal:  HNO       Date:  2020-01       Impact factor: 1.284

Review 7.  Pediatric sensorineural hearing loss, part 2: syndromic and acquired causes.

Authors:  B Y Huang; C Zdanski; M Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2011-05-19       Impact factor: 3.825

8.  [Intracochlear schwannoma as a cause of a deafness: a case report].

Authors:  S Knipping; A Fabricius; S Kösling; M Bloching
Journal:  HNO       Date:  2007-08       Impact factor: 1.284

Review 9.  Meta-analysis on the clinical outcomes in patients with intralabyrinthine schwannomas: conservative management vs. microsurgery.

Authors:  Émilie Gosselin; Anastasios Maniakas; Issam Saliba
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-12       Impact factor: 2.503

10.  Enteroviruses and sudden deafness.

Authors:  Ami Schattner; Doron Halperin; Dana Wolf; Oren Zimhony
Journal:  CMAJ       Date:  2003-05-27       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.